Carrie Wade
      OUR PEOPLE

      Dr. Carrie Wade

      Doctorate in Pharmacology and Neuroscience

      Head of Scientific Engagement

      Contact

      Carrie Wade is Head of Scientific Engagement at Philip Morris International. She leads her team in developing strategies to realize the company's mission of a smoke-free future.​

      Carrie obtained a PhD in Pharmacology and Neuroscience and pursued an MA in Public Health following a postdoc at The Scripps Research Institute. Prior to her role at PMI, she worked as the Principal Scientist in Scientific Affairs at JUUL Labs, where she engaged with lawmakers and stakeholders on U.S. FDA’s regulatory processes.​

      Additionally, Carrie was the director of harm reduction policy at R-street, a think tank in Washington D.C., where she specialized in tobacco and drug policy.​

      At PMI, Carrie stays up to date on global public health discussions to ensure she can leverage the success of tobacco harm reduction strategies. This includes engaging with governments, scientists and regulators as well as internal stakeholders.

      Latest Publications

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.